Encouraging a Pull incentive in the US: Now is the time for a note from you or your company

Dear All:

You are doubtless now familiar with all the reasons why we need pull incentives for AMR-related products (as background, see this blog). We don’t yet have anything beyond the US GAIN act and it alone will not suffice.

In the US, there are discussions this week in the House of Representatives on reauthorizing PAHPA, the Pandemic and All-Hazards Preparedness Reauthorization Act. Language about market entry rewards (specifically, Transferable Conveyance Awards, TCAs, the new language for transferable exclusivity vouchers) has been in and out of the revised Act, but is currently NOT included.

Although TCAs are not perfect, they appear to be the best way for the US to implement something that approximates the idea of a Market Entry Reward (MER) that was proposed by DRIVE-AB for AMR-related products. If implemented with suitable care, it seems obvious that you could use a TCA to provide the type of delinked payments that are at the heart of the MER idea. If you agree with this viewpoint, today would be a really good day for you (or your company’s CEO) to send a note (separately) to any or all of the the staffers working for these representatives:

  • Rep. Doris Matsui (D-CA): megan.herber@mail.house.gov
  • Rep. Anna Eshoo (D-CA): rachel.fybel@mail.house.gov
  • Rep. Tony Cardenas (D-CA): Jacqueline.Usyk@mail.house.gov
  • Rep. Diane DeGette (D-CO): michelle.greenhalgh@mail.house.gov
  • Rep. Brett Guthrie (R-KY): sophie.trainor@mail.house.gov
  • Rep .Leonard Lance (R-NJ): Robert.Butora@mail.house.gov
  • Rep. Chris Collins (R-NY): charlotte.pineda@mail.house.gov
  • Rep. Marsha Blackburn (R-TN): meghan.stringer@mail.house.gov

David Shlaes has posted a good set of talking points on his Perfect Storm blog. You could use those ideas as well as the materials cited above to help you write a brief message regarding your work in this area, your geography (if relevant to the given Representative), your concern about the negative economics of work in this area, and the value that a Pull incentive such as the TCA would have for you or your company would be appropriate.  

Separately, see the Upcoming Meetings list … a detailed summary from last summer’s NIAID PK-PD workshop has now been published.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:


Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top